GSK withdraws sNDA for prostate cancer drug Avodart
Wednesday, November 25, 2009 09:00 IST London
GlaxoSmithKline (GSK) announced that in order to provide an update to the application, the company is withdrawing its US Supplemental New Drug Application (sNDA) for Avodart (dutasteride) for prostate cancer risk